medigraphic.com
ISSN 1870-2821 (Print)
Organo Oficial de la Asociación Mexicana de Mastología

2006, Number 1

<< Back Next >>

Rev Mex Mastol 2006; 1 (1)

Second Revision of the National Consensus Over Diagnosis and Treatment of the Mammary Cancer

Cárdenas SJ, Sandoval GF

Language: Spanish
References: 42
Page: 169-174
PDF size: 163.27 Kb.


Text Extraction

No abstract


REFERENCES

  1. Primer Consenso Nacional sobre Tratamiento del Cáncer Mamario. Rev Inst Nal Cancerol (Mex) 1995; 41 (3): 136-145.

  2. Primera Revisión del Consenso Nacional Sobre Tratamiento del Cáncer Mamario. Revista Ginecología y Obstetricia de México 2002; 70: 349-358.

  3. Ferlay J, Bray F, Parkin DM, Pisan P, ed. Globocan 2000: Cancer Incidence and Mortality Worldwide. IARC Cancer Bases No. 5. IARC Press 2001.

  4. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000; 355: 1822-23.

  5. Norma Oficial Mexicana NOM-041-SSA-2-2002 para la Prevención, Diagnóstico, Tratamiento, Control y Vigilancia Epidemiológica del Cáncer de Mama. México, Secretaría de Salud 2003: 6-7.

  6. Kinsinger LS, Harris R. Chemoprevention of Breast Cancer. Summary of the Evidence. Annals of Internal Medicine 2002; 137: 59-67.

  7. Kerlikowske K, Grady D, Rubin S. Efficacy of screening mammography: A meta-analysis. JAMA 1995; 273: 149-154.

  8. BIRADS atlas, American College of Radiology. Fourth edition 2003.

  9. Connolly JL. Recommendations for the reporting of breast carcinoma. Pathology Case Reviews 1998; 3 (5): 241.

  10. Prognostic factors in breast cancer College of American Pathologists consensus statement 1999. Arch Pathol Lab Med 2000; 124: 966-78.

  11. Le Doussal V, Tubiana HM, Friedman S et al. Prognostic value of histologic grade nuclear components of Scarff-Bloom. Richardson. An improved score modification based on a multivariable analysis of 1,262 invasive ductal breast carcinomas. Cancer 1989; 64: 1914-1921.

  12. Slamon D, Clark G, Wongs et al. Human Breast Cancer, Correlation of relapse and survival with amplification of the Her 2 Neu oncogene. Science 1987; 235: 177-182.

  13. Silverstein et al. DCIS Prognostic Index. Cancer 1996; 77 (11): 2267-2274.

  14. Consensus Conference on the Classification of Ductal Carcinoma in situ. Cancer 1997; 80: 1798-1802.

  15. Índice pronóstico de la Universidad del Sur de California/Van Nuys. Am J Surg 2003; 186: 337-343.

  16. Greene PC, Page DL, Flemming ID et al. AJCC Cancer Staging Manual. Sixth Edition. Publisher by Springer-Verlag, New York 2002.

  17. Veronesi U, Paganelli G, Galimberti V et al. Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 1997; 349: 1984-1987.

  18. Chen AM, Meric F et al. Breast-conserving therapy alter neoadjuvant chemotherapy: the M.D. Anderson Cancer Center experience. Breast Cancer Research and Treatment 2003: 82 (Suppl 1).

  19. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, Senn HJ and Panel Members Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Annals of Oncology 2005; 16 (10): 1569-1583.

  20. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 1998; 351: 1451-1467.

  21. Early Breast Cancer Trialists’ Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998; 352: 930-942.

  22. Martin M, Pienkowski T, Mackey J et al. Adjuvant Docetaxel for Node Positive Breast Cancer. N Engl J Med 2005; 352: 2302-13.

  23. Thürlimann BJ, Keshaviah A, Mouridsen H. BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. ASCO abs 511, 2005.

  24. Bonneterre J et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study. J Clin Oncol 2000; 18 (22): 3748-3757.

  25. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005; 365 (9453): 60-2.

  26. Goss PE, Ingle JN, Martino S et al. Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262-1271.

  27. Winer EP, Hudis C, Harold J et al. American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase inhibitors in the Adjuvant Setting. JCO 2003; 21: 2597-2599.

  28. Coombes RCh, Hall E et al for the Intergroup Exemestane Study. A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. NEJM 2004; 350: 1081-1092.

  29. Bonadonna G, Veronesi U, Branbilla C et al. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82: 1539-45.

  30. Hortobagyi GN, Buzdar AU. Locally advanced breast cancer: a review including the M.D. Anderson experience. In: High Risk Breast Cancer. (Ragaz J, Ariel IM, eds). Berlin: Springer-Verlag, 1991: 382-415.

  31. Nabholtz JM, Falkson G, Campos D et al. A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first line chemotherapy for MBC Proc. ASCO 1999; abs. 485, Vol. 18 pag. 127th.

  32. Extra JM et al. Docetaxel plus Herceptin vs Docetaxel alone as first line treatment HER 2 positive metastatic breast cancer (MBC). Eur J Cancer 2004; 2: 125-239.

  33. NSABP-B-31: Phase III Randomized Study of Doxorubicin and Cyclophosphamide Followed By Paclitaxel With or Withouf Trastuzumab (Herceptin) in Women With Node-Positive Breast Cancer That Overexpresses HER2. ASCO 2005.

  34. Martin M, Pienkowski T et al for the Breast Cancer International Research Group 001 Investigators Adjuvant Docetaxel for Node-Positive Breast Cancer. NEJM 2005; 352: 2302-2313.

  35. Albain K, Nag S, Calderillo G et al. Global Phase III Study of gemcitabine plus paclitaxel vs paclitaxel as front line therapy for metastatic breast cancer: First report of overall survival. ASCO 2004 (abst 510).

  36. Goldstein L. The role of sequential single-agent chemotherapy in the management of advanced breast cancer, Educational Book. Am Soc Clin Oncol 2003; 39: 122-124.

  37. Body JJ, Bartl R, Burckhardt P et al. Current use of biphosphonates in oncology: International Bone and Cancer Study Group. J Clin Oncol 1998; 16: 3890-3899.

  38. Recht A, Edge SB. Evidence-based indications for postmastectomy irradiation. Surg Clin N Am 2003; 83: 995-1013.

  39. Rutqvtst LE, Rose C, Cavallin-Stahl E. A systematic overview of radiation therapy effects in breast cancer. Acta Oncologica 2003; 42 (5/6): 532-545.

  40. Junda W. Breast Cancer in pregnancy: a Literature, Review. Archives of Surgery 2003; 138: 91-98.

  41. Narod SA, Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 2005; 23: 1659-1663.

  42. Shhwartz MD, Lerman C, Brogan B et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004; 22: 1823-1829.




2020     |     www.medigraphic.com